Alimentiv and Summit collaborate to tackle liver disease NASH
Drug development programs will be driven forward by a collaboration between Alimentiv Inc. and Summit…
Drug development programs will be driven forward by a collaboration between Alimentiv Inc. and Summit…
A conditional and exclusive license agreement to develop and commercialize a drug to treat nonalcoholic…
Two preclinical articles have been published in different journals for treatments being developed by French…
Despite several high-profile trial failures in the field, multiple players are getting close to the…
Medical imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound have…
Patients with the chronic liver disease NASH must now wait even longer for an approved…
The Dutch biotech NorthSea Therapeutics has raised a €36M ($40M) Series B round to fund…
Update (17/12/2019): Promethera has increased the total raised in its Series D round to €47.2M…
Liver diseases are on the rise. Although many drug candidates are being developed, preclinical toxicity,…
Nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease (NAFLD) and…
Genfit is poised to become the first company to get a treatment for NASH to…
The US-Chinese company Terns Pharmaceuticals will develop and commercialize Genfit’s phase III drug elafibranor for…